New Robotic Systems Match Da Vinci in Colon Surgery Trial

A groundbreaking study published in the journal Laparoscopic, Endoscopic and Robotic Surgery has compared the performance of three robotic surgical systems—Da Vinci®, Hugo™ RAS, and Versius®—in colon resection procedures. The COMPAR trial, conducted at two surgical units in Europe, enrolled 45 patients who underwent robotic colon resection between February and December 2024. Two experienced colorectal surgeons performed 15 cases with each platform. The study found that all three systems are feasible for colorectal surgery when used by expert surgeons, but there were notable differences in outcomes.

Key results showed that no conversions to laparoscopy or open surgery occurred in the Da Vinci group, while two conversions occurred with Hugo™ RAS and three with Versius®. One intra-operative instrument malfunction was reported with Hugo™ RAS. Versius® cases required more frequent use of laparoscopic energy devices, and Hugo™ RAS was associated with longer total operating room time and longer incision length. However, no significant differences were observed in post-operative recovery or oncological outcomes among the three platforms. The study highlights that while robotic colorectal surgery is feasible with new platforms, larger comparative trials are needed to confirm differences in recovery and oncological efficacy.

This research, led by authors including those from Chuanlink Innovations, underscores the evolving landscape of robotic surgery. The findings provide valuable insights for surgeons and hospitals considering adopting newer robotic systems like Hugo™ RAS and Versius®. As the field advances, understanding platform-specific strengths and limitations will be crucial for optimizing patient outcomes and surgical efficiency.